When the Scientist Is an Agent: Governing AI Before It Reaches the IND
Ono Pharmaceutical's rollout of agentic AI to every discovery scientist exposes a governance gap that sits upstream of any device or wearable regulation.
Find here all our blog posts tagged with: drug discovery.
AI Drug Discovery's Capital Boom Sits Outside the Regulatory Perimeter, Not Ahead of It
Discovery-stage AI funding is surging, but the mismatch compliance leaders should track is structural, not a simple case of regulation lagging money.
The Traceability Debt Building Inside AI-Native Drug Discovery
Closed-loop AI discovery platforms are compressing timelines faster than biopharma governance functions can build the audit trail regulators will eventually demand.
The Documentation Debt AI Drug Discovery Keeps Repeating
AI drug discovery's funding-to-approval gap echoes a governance failure regulators have already documented in medical devices, and the fix is the same.
The AI Drug Discovery Boom Is Outrunning Trial Execution
Generative AI is accelerating molecule design, but no AI-discovered drug has cleared trials, and regulators have yet to define how AI governs the trials themselves.
The Governance Gap Behind FDA's AI Device Surge
FDA's AI-enabled device authorizations are scaling faster than lifecycle governance infrastructure, and the same gap is now stalling AI drug discovery approvals.
